洛铂联合重组人血管内皮抑素胸腔内注射治疗肺癌恶性胸腔积液临床研究

Clinical Study of Intrapleural Injection of Lobaplatin Combined with Recombinant Human Endostatin(endostar) in Treatment of Lung Cancer with Malignant Pleural Effusion

目的:研究洛铂联合重组人血管内皮抑素(恩度)治疗肺癌恶性胸腔积液的有效性和安全性。方法:对确诊为肺癌恶性胸腔积液的63例患者进行分析,采用胸腔内注射治疗方法,其中32例注入洛铂和恩度(A组),31例注入顺铂和恩度(B组),比较两组间疗效、生活质量和毒副作用。结果:洛铂和恩度组与顺铂和恩度组在疗效和生活质量改善上比较差异无统计学意义(P>0.05),在毒副作用方面,洛铂和恩度组白细胞(WBC)减少、贫血、恶心呕吐发生率较顺铂和恩度组低,差异有统计学意义(P<0.05)。结论:洛铂联合恩度胸腔内注射治疗肺癌恶性胸腔积液疗效与顺铂联合恩度相当,毒副作用较轻。

Objective： To study the efficacy and safety of intrapleural injection of lobaplatin combined with endostar in treatment of lung cancer with malignant pleural effusion. Methods： Sixty-three patients diagnosed lung cancer with malignant pleural effusion were treated by the way of intrapleural injection. The subjects were divided into two groups： 32 cases were injected lobaplatin and endostar （A group）, 31 cases were injected cisplatin and endostar （B group）. The clinical efficacy, quality of life and toxic reaction were compared between groups. Results： The clinical efficacy and quality of life were not significantly different between two groups （P〉0.05）. The incidences of WBC reduction, hypohemia, sicchasia and vomit were significant higher in B group than that in A （P〈 0.05）. Conclusion： Lobaplatin combined with endostar therapy showed almost the same clincal efficacy compared to the therapy of cisplatin combined with endostar in treatment of lung cancer with malignant pleural effusion, but with less side effect.